Events
-
2026/06/02 Correctseq
Shanghai, June 2, 2026 — CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for severe diseases, announced that the first sickle cell disease (SCD) patient being treated in China with its high-precision base-editing therapy CS-206 has remained free of vaso-occlusive crises (VOCs) for more than 15 months following engraftment. Starting from 60 Days after the last red-cell transfusion, the patient has remained free from VOCs and anemia for 13 consecutive months, achieving the primary efficacy endpoint. The follow-up data demonstrated favorable safety and efficacy of CS-206.
-
2026/05/11 Correctseq
May 11, 2026, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announ
-
2026/04/09 Correctseq
In a breakthrough for gene therapy, the international academic journal Nature has published a landmark clinical study detailing the successful use of a novel base-editing drug to treat β-thalassemia.J
-
2025/12/01 Correctseq
CorrectSequence Therapeutics to Participate in the 67th ASH Annual Meeting
December 1, 2025, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aiming to use the innovative gene editing technology to help people with severe diseases,
-
2025/11/07 Correctseq
The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
Shanghai, China, November 6, 2025 — CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced that the first patient in its Investigator-Initiated Trial (IIT) of the base-editing therapy CS-121 targeting APOC3 for chylomicronemia / hypertriglyceridemia has successfully completed dosing and been discharged from the hospital.
-
2025/09/12 Correctseq
ShanghaiTech Scientists Take Major Step Forward in High-precision Mitochondrial DNA Editing
A research team led by Assistant Professor Yang Bei at the School of Life Science and Technology (SLST) and Shanghai Institute for Advanced Immunochemical Studies (SIAIS) and Professor Chen Jia at SLST, ShanghaiTech University, has achieved a significant progress in mitochondrial DNA (mtDNA) editing.
-
2025/08/26 Correctseq
CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced the successful treatment of the first sickle cell disease (SCD) patient using its high-precision base-editing therapy CS-101.
-
2025/06/10 Correctseq
CorrectSequence Therapeutics to Participate in EHA2025 Congress
June 10, 2025, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aiming to use the innovative gene editing technology to help people with severe diseases, announced an oral presentation at the EHA2025 Congress, taking place June 12 – 15, 2025, in Milan, Italy.